Q-omics provides the consensus-scored GALNT11 profile across patient tissues and cancer cell-line models. GALNT11 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GALNT11 is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, GALNT11 RNA expression shows 20,599 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KICH, and UVM as cancer lineages where GALNT11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GALNT11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GALNT11 survival associations across molecular data types. GALNT11 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GALNT11 RNA expression–survival associations across cancer types. High GALNT11 expression shows unfavorable associations in CESC, UVM and HNSC, but favorable associations in KIRP, KIRC and LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for GALNT11 RNA expression.
This table summarizes GALNT11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GALNT11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GALNT11 shows lower tumor expression in KICH, THCA and BRCA and higher tumor expression in LIHC, CHOL and COAD. The KICH box plot shows higher GALNT11 RNA expression in normal versus tumor tissue (log2 FC = −1.577, t-test p < 0.001).
This table shows molecular features associated with GALNT11 in patient tissues and cancer cell lines. In patient samples, GALNT11 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GALNT11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
